Chemical synthesis of 7-ethyl-10-hydroxycamptothecin derivative

被引：0

作者：

Kuang, Hao ^{[1
]}

Wang, Jisheng ^{[1
]}

Hong, Zhiming ^{[2
]}

Li, Haisong ^{[1
]}

机构：

[1] Beijing Univ Chinese Med, Beijing, Peoples R China

[2] Guangzhou Univ Chinese Med, Shenzhen, Peoples R China

来源：

PRZEMYSL CHEMICZNY | 2024年 / 103卷 / 02期

关键词：

camptothecin; 7-ethyl-10-hydroxy-camptothecin; ethylene glycol; chemical synthesis; click reaction; CANCER; DRUG; NANOPARTICLES; GLUTATHIONE; IRINOTECAN; RESISTANT;

D O I：

10.15199/62.2024.2.6

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

An 7-Et-10-hydroxycamptothecin (I) derivative was synthesized with a high yield (up to 88%) by nucleophilic substitution by using ethylene glycol as starting material. The OH group was introduced at the C-10 position of camptothecin structure through nucleophilic substitution and an glucose azide was used for the following click reaction.

引用

页码：262 / 265

页数：4

共 50 条

[41] 7-Ethyl-10-Hydroxycamptothecin, A DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth
Wang, Airong
Li, Lingling
Li, Mengya
Wang, Shujuan
Wang, Chong
FRONTIERS IN PHARMACOLOGY, 2021, 12
[42] The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver
Girard, Hugo
Villeneuve, Lyne
Court, Michael H.
Fortier, Louis-Charles
Caron, Patrick
Hao, Qin
von Moltke, Lisa L.
Greenblatt, David J.
Guillemette, Chantal
DRUG METABOLISM AND DISPOSITION, 2006, 34 (07) : 1220 - 1228
[43] Synthesis and Biological Evaluation of Novel 10-Substituted-7-ethyl-10-hydroxycamptothecin (SN-38) Prodrugs
Zhou, Mo
Liu, Meixia
He, Xinhua
Yu, Hong
Wu, Di
Yao, Yishan
Fan, Shiyong
Zhang, Ping
Shi, Weiguo
Zhong, Bohua
MOLECULES, 2014, 19 (12) : 19718 - 19731
[44] Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line
Kohara, H
Tabata, M
Kiura, K
Ueoka, H
Kawata, K
Chikamori, M
Aoe, K
Chikamori, K
Matsushita, A
Harada, M
CLINICAL CANCER RESEARCH, 2002, 8 (01) : 287 - 292
[45] A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: Application to plasma and brain pharmacokinetics
Goldwirt, Lauriane
Lemaitre, Florian
Zahr, Noel
Farinotti, Robert
Fernandez, Christine
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2012, 66 : 325 - 333
[46] SEQUENCE-DEPENDENT MODULATION OF ANTICANCER DRUG ACTIVITIES BY 7-ETHYL-10-HYDROXYCAMPTOTHECIN IN AN HST-1 HUMAN SQUAMOUS CARCINOMA CELL-LINE
MASUMOTO, N
NAKANO, S
ESAKI, T
TATSUMOTO, T
FUJISHIMA, H
BABA, E
NAKAMURA, M
NIHO, Y
ANTICANCER RESEARCH, 1995, 15 (02) : 405 - 409
[47] Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats
Kaneda, N
Hosokawa, Y
Yokokura, T
Awazu, S
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 1997, 20 (09) : 992 - 996
[48] Case Report: 7-Ethyl-10-Hydroxycamptothecin, a DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth
Wang, Airong
Li, Lingling
Li, Mengya
Wang, Shujuan
Wang, Chong
FRONTIERS IN PHARMACOLOGY, 2021, 12
[49] Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes
Hanioka, N
Ozawa, S
Jinno, H
Tanaka-Kagawa, T
Nishimura, T
Ando, M
Sawada, JI
DRUG METABOLISM AND DISPOSITION, 2002, 30 (04) : 391 - 396
[50] Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic cancer cell lines and patient-derived xenografts
Zhang, Linshi
Zhou, Jiarong
Yan, Yingcai
Zhou, Xiaohu
Zhou, Quan
Du, Rong
Hu, Shiqi
Ge, Wenhao
Huang, Yu
Xu, Hao
Kong, Yang
Zheng, Huilin
Ding, Yuan
Shen, Youqing
Wang, Weilin
CANCER LETTERS, 2019, 465 : 36 - 44

← 1 2 3 4 5 →